Akebia Therapeutics to Present at the Leerink Partners 2026 Global Healthcare Conference
Rhea-AI Summary
Akebia Therapeutics (NASDAQ: AKBA) said its CEO John P. Butler and CFO/Chief Business Officer Erik Ostrowski will participate in a Fireside Chat at the Leerink Partners 2026 Global Healthcare Conference on March 9, 2026 at 8:00 AM ET in Miami.
A webcast will be available via the company’s Investors website following the conference. The conference runs March 8-11, 2026.
Positive
- None.
Negative
- None.
News Market Reaction – AKBA
In the Mar 3 session, AKBA declined 3.17%, reflecting a moderate negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Feb 26 | Quarterly earnings | Positive | +9.1% | Stronger 2025 revenues and cash with guidance for Vafseo growth. |
| Feb 19 | Earnings date set | Neutral | +0.0% | Announcement of timing and access details for earnings call. |
| Feb 04 | Conference appearance | Neutral | -2.8% | Management participation in Guggenheim biotech summit fireside chat. |
| Feb 02 | Inducement grants | Neutral | +2.2% | Stock option inducement awards to new employees under Nasdaq rules. |
| Jan 12 | Pipeline update | Positive | -7.9% | Vafseo access growth and multiple mid‑ to late‑stage trial milestones. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Earnings and fundamental updates have sometimes driven sizable moves, with at least one notably negative reaction despite detailed pipeline and commercial progress.
Over the last few months, Akebia has highlighted Vafseo commercial ramp, rare kidney disease pipeline progress, and detailed 2025 financials. An earnings report on Feb 26, 2026 saw a 9.09% gain, while broader 2026 pipeline updates on Jan 12, 2026 coincided with a -7.89% move. Prior conference participation and inducement grants produced modest price changes. Today’s conference appearance fits the pattern of ongoing investor outreach rather than a new fundamental inflection point.
AI-generated analysis. How Rhea-AI works. Not financial advice.
CAMBRIDGE, Mass., March 03, 2026 (GLOBE NEWSWIRE) -- Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced that John P. Butler, Chief Executive Officer and Erik Ostrowski, Chief Financial and Chief Business Officer, will participate in a Fireside Chat at the Leerink Partners 2026 Global Healthcare Conference on Monday, March 9 at 8:00 AM ET.
A webcast of the presentation can be accessed through the “Investors” section of Akebia’s website at https://ir.akebia.com following the conference.
The Leerink Partners 2026 Global Healthcare Conference will take place March 8-11, 2026, in Miami.
About Akebia Therapeutics
Akebia Therapeutics, Inc. is a fully integrated biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease. Akebia was founded in 2007 and is headquartered in Cambridge, Massachusetts. For more information, please visit our website at www.akebia.com, which does not form a part of this release.
Akebia Therapeutics Contact
Mercedes Carrasco
mcarrasco@akebia.com
